Robert A Harrington

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Chest 126:513S-548S. 2004
  2. ncbi request reprint Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes
    Robert A Harrington
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Semin Thromb Hemost 30:639-47. 2004
  3. ncbi request reprint Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Arch Intern Med 166:2027-34. 2006
  4. ncbi request reprint Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:641-7. 2006
  5. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
  6. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
  7. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
  8. pmc Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
    Circulation 125:749-56. 2012
  9. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
  10. doi request reprint Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:448-58. 2011

Collaborators

Detail Information

Publications152 found, 100 shown here

  1. ncbi request reprint Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Chest 126:513S-548S. 2004
    ..5) [Grade 2A]...
  2. ncbi request reprint Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes
    Robert A Harrington
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Semin Thromb Hemost 30:639-47. 2004
    ..The major focus of this article will be on examining key lessons from the trials in each of these areas as well as presenting a series of questions that still require answers from either ongoing or future research...
  3. ncbi request reprint Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Arch Intern Med 166:2027-34. 2006
    ..We sought to determine recent trends in adherence to guideline-based therapies for NSTE ACS...
  4. ncbi request reprint Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:641-7. 2006
    ..We sought to determine the prevalence, predictors, and outcomes of patients with NSTEMI and insignificant CAD...
  5. ncbi request reprint Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
  6. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  7. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
    ..All MI types were associated with worse short- and long-term outcomes. Characterization of the type of MI provides an opportunity for more informed interpretation of clinical trial results and improved planning for future trials...
  8. pmc Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
    Circulation 125:749-56. 2012
    ..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes...
  9. ncbi request reprint Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  10. doi request reprint Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circ Cardiovasc Qual Outcomes 4:448-58. 2011
    ..We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials...
  11. doi request reprint Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    JACC Cardiovasc Interv 5:927-35. 2012
    ....
  12. doi request reprint Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice
    Tracy Y Wang
    Duke Clinical Research Institute, Terrace Level, Durham, NC 27705, USA
    Circulation 119:2454-62. 2009
    ..The incidence, severity, and prognostic significance of acquired thrombocytopenia during ACS in community practice have not been well defined...
  13. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009
    ....
  14. ncbi request reprint Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Venu Menon
    Division of Cardiology, University of North Carolina at Chapel Hill, 27599, USA
    Chest 126:549S-575S. 2004
    ....
  15. doi request reprint Platelet inhibition with cangrelor in patients undergoing PCI
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 361:2318-29. 2009
    ..This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition...
  16. ncbi request reprint A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  17. ncbi request reprint Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  18. ncbi request reprint Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    J Interv Cardiol 20:299-306. 2007
    ..Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear...
  19. ncbi request reprint Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft
    Rajendra H Mehta
    Division of Cardiology, Department of Internal Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Circulation 114:I396-401. 2006
    ..The influence of an internal mammary artery (IMA) graft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unknown...
  20. doi request reprint Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:369-74. 2008
    ..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
  21. ncbi request reprint Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology and the Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina USA
    Am J Cardiol 98:1172-6. 2006
    ..In conclusion, despite the overall increase in the use of early catheterization, the gap between the use of an early invasive strategy in the highest and lowest risk patients remains large and tends to increase over time...
  22. ncbi request reprint Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 100:1538-42. 2007
    ..These differences should be kept in context when counseling patients undergoing CABG and may help facilitate targeted strategies to improve short- and long-term mortality risks after CABG...
  23. ncbi request reprint Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE)
    Pierluigi Tricoci
    Division of Cardiology, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Cardiol 99:1389-93. 2007
    ..In conclusion, in this observational analysis, overall ischemic outcomes were similar between the 2 groups, but clinical trials are needed to solve the controversy over optional timing of GP IIb/IIIa inhibitor use...
  24. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  25. doi request reprint Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Circulation 124:280-8. 2011
    ....
  26. ncbi request reprint Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
    Kanwar P Singh
    Division of Cardiology and Duke Clinical Research Institute, Durham, NC 27705, USA
    J Thromb Thrombolysis 21:211-20. 2006
    ..We sought to compare the efficacy and safety of these treatment strategies in a large contemporary population of patients with NSTE ACS...
  27. pmc Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 164:379-386.e1. 2012
    ..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes...
  28. ncbi request reprint Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
    Abdallah G Rebeiz
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Med 116:119-29. 2004
    ..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization...
  29. doi request reprint Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
    Tracy Y Wang
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Circulation 123:722-30. 2011
    ..This analysis examines efficacy and safety of early eptifibatide in the setting of concurrent upstream clopidogrel use...
  30. doi request reprint Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome
    Richard C Becker
    Division of Cardiology and Hematology, Duke University School of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Thromb Haemost 104:976-83. 2010
    ..5 mg twice daily dose. The effect on both D-dimer and F 1.2 was apixaban concentration-and factor Xa inhibition dependent, durable and provided general guidance for dose selection in phase 3 investigation...
  31. ncbi request reprint Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  32. doi request reprint Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
    J Thorac Cardiovasc Surg 136:1149-55. 2008
    ..Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery...
  33. doi request reprint Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:884-892.e1. 2011
    ..Dose adjustment of renally excreted antithrombotic drugs is recommended for patients with reduced renal function. We examined the influence of dose modification on bleeding and efficacy...
  34. doi request reprint Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 366:20-33. 2012
    ..Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation...
  35. ncbi request reprint Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease
    Richard C Becker
    Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, NC 27715, USA
    Thromb Haemost 92:1182-93. 2004
    ..The following review focuses on DX-9065a - first in a class of direct, selective and reversible fXa antagonists - and its potential applications in the management of patients with cardiovascular disease...
  36. ncbi request reprint Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 149:474-81. 2005
    ....
  37. ncbi request reprint Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
    ..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure...
  38. ncbi request reprint Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  39. ncbi request reprint Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative
    E Magnus Ohman
    Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Am Heart J 148:S34-9. 2004
    ..These ACC/AHA guidelines are intended to help physicians make appropriate decisions when diagnosing and treating patients with NSTE ACS...
  40. ncbi request reprint Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock
    Rajendra H Mehta
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:793-6. 2007
    ..This information may help physicians in deciding treatment options for patients with cardiogenic shock and counseling them about their risks...
  41. doi request reprint Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Chest 133:670S-707S. 2008
    ....
  42. doi request reprint Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  43. ncbi request reprint An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A
    L Kristin Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 14:33-42. 2002
    ..We assessed unfractionated heparin infusion regulation by bedside, whole-blood aPTT testing and computerized, algorithmic infusion adjustment, and further evaluated the relationship of achieving the target aPTT with clinical outcomes...
  44. doi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  45. doi request reprint The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Richard C Becker
    Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Chest 133:776S-814S. 2008
    ..For primary prevention in patients with moderate risk for a coronary event, we recommend aspirin, 75-100 mg/d, over either no antithrombotic therapy or vitamin K antagonist (Grade 1A)...
  46. ncbi request reprint Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
    John H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Med 115:613-9. 2003
    ..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...
  47. doi request reprint Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cardiol 31:125-9. 2008
    ..The prognostic value of cardiac troponins (cTn) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and chronic kidney disease (CKD) is debated...
  48. ncbi request reprint Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  49. ncbi request reprint The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 151:1205-13. 2006
    ..We characterized guideline adherence for NSTE ACS by risk status...
  50. doi request reprint Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA
    Circulation 119:2877-85. 2009
    ..After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding...
  51. doi request reprint Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography
    Tracy Y Wang
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 157:716-23. 2009
    ....
  52. doi request reprint Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  53. ncbi request reprint Association between hospital process performance and outcomes among patients with acute coronary syndromes
    Eric D Peterson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    JAMA 295:1912-20. 2006
    ..Selected care processes are increasingly being used to measure hospital quality; however, data regarding the association between hospital process performance and outcomes are limited...
  54. ncbi request reprint Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction
    Manesh R Patel
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 151:316-22. 2006
    ..Cardiac tamponade is a life-threatening complication of acute myocardial infarction (MI). Data on the incidence, risk factors, and outcome of tamponade in patients with acute MI in the fibrinolytic era are limited...
  55. ncbi request reprint Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes
    David E Kandzari
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 96:750-5. 2005
    ....
  56. ncbi request reprint First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation
    Christopher K Dyke
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 105:2385-91. 2002
    ....
  57. ncbi request reprint Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ....
  58. ncbi request reprint Statin use and sex-specific stroke outcomes in patients with vascular disease
    Cheryl D Bushnell
    Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
    Stroke 37:1427-31. 2006
    ..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
  59. doi request reprint Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
    ..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome...
  60. ncbi request reprint A comparison of acute coronary syndrome care at academic and nonacademic hospitals
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am J Med 120:40-6. 2007
    ..We sought to identify hospital characteristics associated with high levels of adherence in order to gain insight into successful processes of care...
  61. ncbi request reprint Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes
    L Kristin Newby
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715 7969, USA
    J Am Coll Cardiol 47:312-8. 2006
    ..We sought to evaluate the association between discordant cardiac marker results and in-hospital mortality and treatment patterns in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  62. doi request reprint Noninvasive, medical management for non-ST-elevation acute coronary syndromes
    Mark Y Chan
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 155:397-407. 2008
    ....
  63. ncbi request reprint Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 98:624-7. 2006
    ....
  64. doi request reprint Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous
    Sergio Leonardi
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 160:65-72. 2010
    ..The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel-controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI...
  65. doi request reprint Long-term clinical outcomes following coronary stenting
    Kevin J Anstrom
    Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
    Arch Intern Med 168:1647-55. 2008
    ..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
  66. ncbi request reprint Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy
    Jeffrey S Berger
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 117:192-9. 2008
    ..We therefore compared the acute mortality and bleeding risks associated with the initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients...
  67. ncbi request reprint Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
    Kenneth W Mahaffey
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
    Eur Heart J 28:425-32. 2007
    ..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery...
  68. doi request reprint Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rap
    Jeffrey S Berger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 158:998-1004.e1. 2009
    ..We examined the safety and tolerability of a novel, direct-acting, reversible, intravenous P2Y12 ADP-receptor antagonist, elinogrel, versus placebo when administered to STEMI patients before primary PCI...
  69. ncbi request reprint Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery
    Abdul R Halabi
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1254-9. 2005
    ..36, 95% confidence interval 2.00 to 2.79, p <0.0001). In conclusion, in contemporary clinical practice, early SVG failure is associated with worse long-term outcomes after CABG...
  70. ncbi request reprint The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Am J Med 112:647-58. 2002
    ..To understand these findings, we performed a meta-analysis of results from four phase 3 trials...
  71. ncbi request reprint Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention
    Can M Nguyen
    Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Am J Cardiovasc Drugs 3:423-36. 2003
    ....
  72. doi request reprint A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:600-8. 2008
    ....
  73. ncbi request reprint Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial
    Thaddeus R Tolleson
    Duke University Medical Center and Clinical Research Institute, Durham, NC 27705, USA
    J Am Coll Cardiol 41:386-93. 2003
    ..We evaluated the relationship between the degree of heparin anticoagulation and clinical efficacy and bleeding in patients undergoing contemporary percutaneous coronary intervention (PCI) with stent implantation...
  74. ncbi request reprint Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview
    John L Petersen
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:89-96. 2004
    ....
  75. ncbi request reprint Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction
    Hung Q Ly
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 95:383-6. 2005
    ..44, 95% confidence interval 0.23 to 0.85, p = 0.014)...
  76. ncbi request reprint Cardiology patient page. Antiplatelet therapy
    Robert A Harrington
    Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
    Circulation 108:e45-7. 2003
  77. ncbi request reprint The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials
    Jacqueline Saw
    Department of Medicine, Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 48:1567-72. 2006
    ..We aimed to evaluate clinical outcomes among peripheral arterial disease (PAD) patients following percutaneous coronary intervention (PCI)...
  78. doi request reprint Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    JAMA 299:1777-87. 2008
    ..Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery...
  79. doi request reprint Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 124:544-54. 2011
    ..045), with less effect of ticagrelor in North America than in the rest of the world...
  80. doi request reprint Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 158:881-886.e1. 2009
    ..Clinical trials of antithrombotic agents for the treatment of ACS routinely assess bleeding as a safety endpoint, but variation in bleeding definitions makes comparison of the relative safety of these agents difficult...
  81. ncbi request reprint Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics
    Robert M Califf
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Health Aff (Millwood) 26:62-74. 2007
    ....
  82. doi request reprint Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Richard C Becker
    Duke Clinical Research Institute, Durham, NC, USA
    Lancet 373:919-28. 2009
    ..We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist...
  83. doi request reprint Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design
    Lynda A Szczech
    Renal Division, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Nephrol Dial Transplant 25:2368-75. 2010
    ..Ferric carboxymaltose (FCM) is a novel IV iron formulation designed to permit larger infusions compared to currently available IV standards such as Venofer(R) (iron sucrose)...
  84. ncbi request reprint Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 5:401-12. 2007
    ....
  85. ncbi request reprint Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
    David F Kong
    Division of Cardiology, Department of Medicine, Duke University Medical Center and Clinical Research Institute, Durham, NC 27710, USA
    Am J Cardiol 92:651-5. 2003
    ..There also is increasing evidence that mortality reductions are preserved at 6 months...
  86. doi request reprint Aldehyde dehydrogenase activity allows reliable EPC enumeration in stored peripheral blood samples
    Thomas J Povsic
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 28:259-65. 2009
    ....
  87. ncbi request reprint International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 101:25-29. 2008
    ....
  88. ncbi request reprint Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction
    Matthew T Roe
    Duke Clinical Research Institute and Division of Cardiology, Duke Medical Center, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 43:549-56. 2004
    ....
  89. ncbi request reprint Myocardial ischemia and infarction
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 44:10A-12A. 2004
  90. ncbi request reprint Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:1555-62. 2004
    ..It is unclear if blood transfusion in anemic patients with acute coronary syndromes is associated with improved survival...
  91. ncbi request reprint Interventional cardiovascular pharmacotherapy: current issues
    Abdallah G Rebeiz
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiovasc Drugs 5:93-102. 2005
    ..Overall, the use of GP IIb/IIIa inhibitors reduces the incidence of thrombotic complications following PCI, is associated with a mortality benefit, but has no impact on the risk of restenosis...
  92. ncbi request reprint The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 150:643-9. 2005
    ..Edifoligide inhibits E2F, a transcription factor that activates cell-cycle genes responsible for neointimal hyperplasia...
  93. ncbi request reprint Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts
    Rajendra H Mehta
    Department of Internal Medicine, Division of Cardiology, Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 152:801-6. 2006
    ..Accordingly, the goal of present study was to evaluate clinical correlates of long-term mortality and to develop a simple bedside tool for risk stratification in patients undergoing SVG interventions...
  94. doi request reprint Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:242-66. 2011
    ..This paper summarizes the symposium proceedings...
  95. ncbi request reprint Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge
    Pierluigi Tricoci
    Division of Cardiology, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC, USA
    Arch Intern Med 166:806-11. 2006
    ....
  96. doi request reprint Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 106:1728-34. 2010
    ..Thus, major emphasis should be on prevention of ARF in patients undergoing CABG...
  97. ncbi request reprint Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor
    Richard C Becker
    Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, NC 27705, USA
    J Thromb Thrombolysis 18:193-7. 2004
    ....
  98. ncbi request reprint The bent stent
    Can M Nguyen
    Division of Cardiology, P O Box 3850, Duke University Medical Center, Durham, NC 27710, USA
    J Invasive Cardiol 14:54-6. 2002
  99. ncbi request reprint Poverty, process of care, and outcome in acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, dDuke University, PO Box 17969, Durham, NC 27715, USA
    J Am Coll Cardiol 41:1948-54. 2003
    ..We sought to determine whether income-based disparities in care processes and outcome exist in patients with acute coronary syndromes...
  100. pmc Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial
    Chiara Melloni
    Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 160:795-803.e2. 2010
    ..Animal models of ischemia/reperfusion have demonstrated that single-dose erythropoietin may reduce infarct size, decrease apoptosis, and increase neovascularization, possibly through mobilization of endothelial progenitor cells...
  101. pmc Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?
    Adrian F Hernandez
    Duke Clinical Research Institute and the Division of Cardiovascular Medicine, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA
    CMAJ 178:1316-9. 2008